SFRP1 and myopia: Genetic and pharmacological approaches were employed using a shRNA against the guinea pig Coch transcript and a specific inhibitor of SFRP1, respectively, to validate the effects of targeting these 2 molecules in FDM, the guinea pig model of nonpathologic myopia with more aggravated phenotypes in comparison to LIM.